Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial

Table 3 The domains of PCOSQ-26 questionnaire at the beginning and after 12 weeks of intervention in people with polycystic ovary syndrome

Variables	Intervention group N = 28	Control group N = 24	95% CI		P**	P***
Variables	Intervention group N = 28	Control group N = 24	Lower	Upper	P**	P***
Emotions domain
Baseline End of trial Change P*	55.67 ± 11.00 61.60 ± 13.71 5.93 ± 13.60 0.029	57.36 ± 19.72 65.84 ± 20.93 8.48 ± 13.41 0.050	-10.89 -13.97 -10.10	7.51 5.48 5.00	0.711 0.386 0.501	0.044
Body hair domain
Baseline End of trial Change P*	58.18 ± 19.87 55.51 ± 19.78 1.32 ± 17.41 0.690	62.14 ± 27.83 70.95 ± 23.82 8.80 ± 16.63 0.016	-21.29 -27.58 -17.01	5.37 -3.29 2.04	0.236 0.014 0.121	0.016
Weight domain
Baseline End of trial Change P*	54.18 ± 19.87 55.51 ± 19.78 1.32 ± 17.41 0.690	62.14 ± 27.83 70.95 ± 23.82 8.80 ± 16.63 0.016	-21.29 -27.58 -17.01	5.37 -3.29 2.04	0.236 0.014 0.121	0.033
Infertility domain
Baseline End of trial Change P*	76.02 ± 20.01 82.52 ± 17.31 6.50 ± 14.22 0.023	76.48 ± 16.41 75.14 ± 20.35 -1.33 ± 15.21 0.670	-10.77 -3.11 -0.36	9.83 17.86 16.05	0.928 0.164 0.061	0.027
Menstrual problems
Baseline End of trial Change P*	54.20 ± 16.69 58.03 ± 16.25 3.82 ± 14.15 0.164	60.56 ± 22.15 65.62 ± 22.26 5.05 ± 24.78 0.328	-17.19 -18.34 -12.27	4.48 3.16 9.81	0.244 0.163 0.823	0.389
Cronbach’s alpha
Baseline End of trial	0.857 0.906	0.926 0.946

P*: p-values for comparison within groups via paired t-test.
P**: p-values for comparison between groups via independent t-test.
P***: p-values based on an ANCOVA model adjusted with baseline value of the outcome, age, marital status, PCOS duration and mean changes in BMI, waist circumference and hip circumference.
CI: confidence interval

ISSN: 1472-6874